January 2012

New data show that roughly one-fifth of tamoxifen-treated male patients with breast cancer stop treatment early because of side effects.

Outpatient management in patients with cancer who have a low risk of severe febrile neutropenia is an effective and safe option to standard inpatient treatment.

The use of a navigation program for an urban safety net breast cancer population has only a moderate effect on the time from symptom presentation to treatment.

Year after year, the John Theurer Cancer Center (JTCC) harnesses the newest technologies and retains world-class oncologists, nurses, and scientists to fulfill its mission of delivering extraordinary care to patients in the community.

New data show that while men are diagnosed with breast cancer at a mere fraction of the rate of women, they tend to have more advanced disease at the time of diagnosis.

The combination of anastrozole and fulvestrant improved survival when used as first-line therapy in postmenopausal women with metastatic HR-positive breast cancer compared with anastrozole alone.

Radiation therapy added to androgen deprivation therapy prolongs overall survival in men with locally advanced or otherwise high-risk prostate cancer.

The developing theme is that bisphosphonates are most effective in postmenopausal patients with HR-positive breast cancer.

Patients who receive a solid organ transplant have about twice the risk of developing cancer as the general population.

Melanoma is one of the most frequent cancers; more than 2 million Americans are treated for skin cancer annually.

In order to design new treatments for prostate cancer and prolong the lives of patients with the disease, researchers are going to have to delve into the tumor microenvironment.

Upfront zoledronic acid is superior to delayed use in postmenopausal women with early breast cancer who are being treated with the aromatase inhibitor letrozole.

Human papillomavirus is perhaps best known as the main cause of cervical cancer, but if recent trends continue, by 2020 HPV will cause more cases of oropharyngeal cancer each year than cervical cancer.

Novel therapeutics, including thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade), have revolutionized the treatment of multiple myeloma.

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

The treatment of diffuse large B-cell lymphoma continues to evolve, as researchers seek to improve upon the current standard of care.

Two novel treatments for advanced melanoma, ipilimumab (Yervoy) and vemurafenib (Zelboraf), were among the top breakthroughs in cancer research in 2011.

Radiotherapy often results in the loss of some salivary gland function, causing hyposalivation and xerostomia.

Much has been made of the difficulties companies, investigators, and patient advocates have in providing access to novel therapies.